{ "nodes": [ [ "4URU The crystal structure of H-Ras and SOS in complex with ligands", "PDB_STRUCTURE" ], [ "EPZ-5676", "COMPOUND" ], [ "trametinib", "DRUG" ], [ "SOS1", "GENE" ], [ "Osteocalcin", "COMPOUND" ], [ "4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide", "COMPOUND" ], [ "sotorasib", "DRUG" ], [ "adagrasib", "DRUG" ], [ "DOT1L", "GENE" ], [ "Permethrin", "DRUG" ], [ "Etoposide", "DRUG" ], [ "venetoclax", "DRUG" ], [ "5DTM Crystal structure of Dot1L in complex with inhibitor CPD1 [4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide]", "PDB_STRUCTURE" ] ], "edges": [ [ [ "SOS1", "Osteocalcin" ], 11.727179000000001 ], [ [ "5DTM Crystal structure of Dot1L in complex with inhibitor CPD1 [4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide]", "DOT1L" ], 7.036307399999999 ], [ [ "DOT1L", "venetoclax" ], 0.38474659, [ [ "Caner Saygin, Hetty E Carraway (2017). Emerging therapies for acute myeloid leukemia. Journal of hematology & oncology, 93. https://doi.org/10.1186/s13045-017-0463-6 PMID: 28420416", "28420416" ], [ "Danielle Shafer, Steven Grant (2016). Update on rational targeted therapy in AML. Blood reviews, 275-83. PMID: 26972558", "26972558" ], [ "Juliana M Benito, Laura Godfrey, Kensuke Kojima, Leah Hogdal, Mark Wunderlich, Huimin Geng, Isabel Marzo, Karine G Harutyunyan, Leonard Golfman, Phillip North, Jon Kerry, Erica Ballabio, Triona Ní Chonghaile, Oscar Gonzalo, Yihua Qiu, Irmela Jeremias, LaKiesha Debose, Eric O'Brien, Helen Ma, Ping Zhou, Rodrigo Jacamo, Eugene Park, Kevin R Coombes, Nianxiang Zhang, Deborah A Thomas, Susan O'Brien, Hagop M Kantarjian, Joel D Leverson, Steven M Kornblau, Michael Andreeff, Markus Müschen, Patrick A Zweidler-McKay, James C Mulloy, Anthony Letai, Thomas A Milne, Marina Konopleva (2015). MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell reports, 2715-27. PMID: 26711339", "26711339" ] ] ], [ [ "DOT1L", "EPZ-5676" ], 70.7363, [ [ "Yaqi Zhang, Yinu Wang, Andres Valdivia, Hao Huang, Daniela Matei (2023). DOT1 L Regulates Ovarian Cancer Stem Cells by Activating β-catenin Signaling. Molecular cancer research : MCR, 140-154. https://doi.org/10.1158/1541-7786.MCR-22-0418 PMID: 36318113", "36318113" ], [ "Yang Si, Corentin Bon, Magdalena Barbachowska, Veronique Cadet-Daniel, Corinne Jallet, Laura Soresinetti, Mikaël Boullé, Magalie Duchateau, Mariette Matondo, Fabrice Agou, Ludovic Halby, Paola B Arimondo (2022). A novel screening strategy to identify histone methyltransferase inhibitors reveals a crosstalk between DOT1L and CARM1. RSC chemical biology, 456-467. https://doi.org/10.1039/d1cb00095k PMID: 35441144", "35441144" ], [ "Yan Yi, Shenglei Ge (2022). Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias. Journal of hematology & oncology, 35. https://doi.org/10.1186/s13045-022-01251-1 PMID: 35331314", "35331314" ], [ "Hetakshi Kurani, Seyedeh Fatemeh Razavipour, Kuzhuvelil B Harikumar, Matthew Dunworth, Andrew J Ewald, Apsra Nasir, Gray Pearson, Derek Van Booven, Zhiqun Zhou, Diana Azzam, Claes Wahlestedt, Joyce Slingerland (2022). DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 1948-1965. https://doi.org/10.1158/1078-0432.CCR-21-1299 PMID: 35135840", "35135840" ], [ "Carrie A Malcom, Anamika Ratri, Joanna Piasecka-Srader, Shaon Borosha, V Praveen Chakravarthi, Nehemiah S Alvarez, Jay L Vivian, Timothy A Fields, M A Karim Rumi, Patrick E Fields (2021). Primitive Erythropoiesis in the Mouse is Independent of DOT1L Methyltransferase Activity. Frontiers in cell and developmental biology, 813503. https://doi.org/10.3389/fcell.2021.813503 PMID: 35111761", "35111761" ], [ "Suresh Chava, Suresh Bugide, Yvonne J K Edwards, Romi Gupta (2021). Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis. Oncogenesis, 48. https://doi.org/10.1038/s41389-021-00339-6 PMID: 34253709", "34253709" ], [ "Katelyn E Heimbruch, Joseph B Fisher, Cary T Stelloh, Emily Phillips, Michael H Reimer, Adam J Wargolet, Alison E Meyer, Kirthi Pulakanti, Aaron D Viny, Jessica J Loppnow, Ross L Levine, John Anto Pulikkan, Nan Zhu, Sridhar Rao (2021). DOT1L inhibitors block abnormal self-renewal induced by cohesin loss. Scientific reports, 7288. https://doi.org/10.1038/s41598-021-86646-9 PMID: 33790356", "33790356" ], [ "Derek H Janssens, Michael P Meers, Steven J Wu, Ekaterina Babaeva, Soheil Meshinchi, Jay F Sarthy, Kami Ahmad, Steven Henikoff (2021). Automated CUT&Tag profiling of chromatin heterogeneity in mixed-lineage leukemia. Nature genetics, 1586-1596. https://doi.org/10.1038/s41588-021-00941-9 PMID: 34663924", "34663924" ], [ "Wanlin Yang, Hongshuang Yu, Jiefang Huang, Xiang Miao, Qiwei Wang, Yanan Wang, Yiji Cheng, Shan He, Fang Zhao, Lijun Meng, Bei Wang, Fengtao Qian, Xiaohui Ren, Min Jin, Yuting Gu, Yanyun Zhang, Wei Cai (2021). Inhibition of Dot1L Alleviates Fulminant Hepatitis Through Myeloid-Derived Suppressor Cells. Cellular and molecular gastroenterology and hepatology, 81-98. https://doi.org/10.1016/j.jcmgh.2021.01.013 PMID: 33497867", "33497867" ], [ "Florian Perner, Jayant Y Gadrey, Yijun Xiong, Charles Hatton, Benjamin K Eschle, Andreas Weiss, Frédéric Stauffer, Christoph Gaul, Ralph Tiedt, Jennifer A Perry, Scott A Armstrong, Andrei V Krivtsov (2020). Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. Blood, 1983-1988. https://doi.org/10.1182/blood.2020006113 PMID: 32575123", "32575123" ] ] ], [ [ "4URU The crystal structure of H-Ras and SOS in complex with ligands", "SOS1" ], 7.036307399999999 ], [ [ "DOT1L", "Permethrin" ], 0.70363074 ], [ [ "SOS1", "trametinib" ], 11.789075, [ [ "Benjamin Schulz, Emily Leitner, Tim Schreiber, Tobias Lindner, Rico Schwarz, Nadine Aboutara, Yixuan Ma, Hugo Murua Escobar, Rupert Palme, Burkhard Hinz, Brigitte Vollmar, Dietmar Zechner (2024). Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer. Cancers. https://doi.org/10.3390/cancers16101901 PMID: 38791980", "38791980" ], [ "Elisabetta Puliga, Chiara De Bellis, Sandra Vietti Michelina, Tania Capeloa, Cristina Migliore, Claudia Orrù, Gian Luca Baiocchi, Giovanni De Manzoni, Filippo Pietrantonio, Rossella Reddavid, Uberto Fumagalli Romario, Chiara Ambrogio, Simona Corso, Silvia Giordano (2024). Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 473-483. https://doi.org/10.1007/s10120-024-01468-8 PMID: 38261067", "38261067" ], [ "Brianna R Daley, Heidi M Vieira, Chaitra Rao, Jacob M Hughes, Zaria M Beckley, Dianna H Huisman, Deepan Chatterjee, Nancy E Sealover, Katherine Cox, James W Askew, Robert A Svoboda, Kurt W Fisher, Robert E Lewis, Robert L Kortum (2023). SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status. Proceedings of the National Academy of Sciences of the United States of America, e2313137120. https://doi.org/10.1073/pnas.2313137120 PMID: 37972068", "37972068" ], [ "Guy Chowers, Gadi Abebe-Campino, Hana Golan, Asaf Vivante, Shoshana Greenberger, Michalle Soudack, Galia Barkai, Ilana Fox-Fisher, Dong Li, Michael March, Mark R Battig, Hakon Hakonarson, Denise Adams, Yoav Dori, Adi Dagan (2023). Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition. Pediatric research, 1911-1915. https://doi.org/10.1038/s41390-022-01986-0 PMID: 35246606", "35246606" ], [ "Michele Lioncino, Adelaide Fusco, Emanuele Monda, Diego Colonna, Michelina Sibilio, Martina Caiazza, Daniela Magri, Angela Carla Borrelli, Barbara D'Onofrio, Maria Luisa Mazzella, Rossella Colantuono, Maria Rosaria Arienzo, Berardo Sarubbi, Maria Giovanna Russo, Giovanni Chello, Giuseppe Limongelli (2022). Severe Lymphatic Disorder and Multifocal Atrial Tachycardia Treated with Trametinib in a Patient with Noonan Syndrome and SOS1 Mutation. Genes. https://doi.org/10.3390/genes13091503 PMID: 36140671", "36140671" ], [ "Yixuan Ma, Benjamin Schulz, Nares Trakooljul, Moosheer Al Ammar, Anett Sekora, Sina Sender, Frieder Hadlich, Dietmar Zechner, Frank Ulrich Weiss, Markus M Lerch, Robert Jaster, Christian Junghanss, Hugo Murua Escobar (2022). Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers. https://doi.org/10.3390/cancers14184467 PMID: 36139627", "36139627" ], [ "Adelina Plangger, Barbara Rath, Sandra Stickler, Maximilian Hochmair, Clemens Lang, Lukas Weigl, Martin Funovics, Gerhard Hamilton (2022). Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines. Discover. Oncology, 84. https://doi.org/10.1007/s12672-022-00550-w PMID: 36048281", "36048281" ], [ "Takamasa Koga, Kenichi Suda, Toshio Fujino, Shuta Ohara, Akira Hamada, Masaya Nishino, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Takeo Arita, Michael Gmachl, Marco H Hofmann, Junichi Soh, Tetsuya Mitsudomi (2021). KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 1321-1332. https://doi.org/10.1016/j.jtho.2021.04.015 PMID: 33971321", "33971321" ], [ "Yoav Dori, Chris Smith, Erin Pinto, Kristen Snyder, Michael E March, Hakon Hakonarson, Jean Belasco (2020). Severe Lymphatic Disorder Resolved With MEK Inhibition in a Patient With Noonan Syndrome and SOS1 Mutation. Pediatrics. https://doi.org/10.1542/peds.2020-0167 PMID: 33219052", "33219052" ], [ "Gabrielle S Wong, Jin Zhou, Jie Bin Liu, Zhong Wu, Xinsen Xu, Tianxia Li, David Xu, Steven E Schumacher, Jens Puschhof, James McFarland, Charles Zou, Austin Dulak, Les Henderson, Peng Xu, Emily O'Day, Rachel Rendak, Wei-Li Liao, Fabiola Cecchi, Todd Hembrough, Sarit Schwartz, Christopher Szeto, Anil K Rustgi, Kwok-Kin Wong, J Alan Diehl, Karin Jensen, Francesco Graziano, Annamaria Ruzzo, Shaunt Fereshetian, Philipp Mertins, Steven A Carr, Rameen Beroukhim, Kenichi Nakamura, Eiji Oki, Masayuki Watanabe, Hideo Baba, Yu Imamura, Daniel Catenacci, Adam J Bass (2018). Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nature medicine, 968-977. https://doi.org/10.1038/s41591-018-0022-x PMID: 29808010", "29808010" ] ] ], [ [ "SOS1", "sotorasib" ], 11.856758000000001, [ [ "Gerhard Hamilton, Marie-Therese Eggerstorfer, Sandra Stickler (2024). Development of PROTACS degrading KRAS and SOS1. Oncology research, 1257-1264. https://doi.org/10.32604/or.2024.051653 PMID: 39055890", "39055890" ], [ "Yan Lv, Zixuan Yang, Yiming Chen, Xuepei Ma, Mengqi Guo, Chengwei Zhang, Xiaolin Jiang, Chengli Wang, Zhuoyue Li, Zhengfu Tai, Xiao Wang, Siqi Zhang, Shumin Ma, Chong Qin (2024). A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor. Journal of medicinal chemistry, 2487-2511. https://doi.org/10.1021/acs.jmedchem.3c01598 PMID: 38316747", "38316747" ], [ "Sandra Stickler, Barbara Rath, Gerhard Hamilton (2024). Targeting KRAS in pancreatic cancer. Oncology research, 799-805. https://doi.org/10.32604/or.2024.045356 PMID: 38686056", "38686056" ], [ "Fei Xiao, Kailiang Wang, Xinjuan Wang, Huijuan Li, Zhilong Hu, Xiaoming Ren, Wei Huang, Teng Feng, Lili Yao, Jing Lin, Chunlai Li, Zhuanzhuan Zhang, Liufeng Mei, Xiaotian Zhu, Wenge Zhong, Zhi Xie (2024). Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers. Molecular cancer therapeutics, 1703-1716. https://doi.org/10.1158/1535-7163.MCT-24-0049 PMID: 39087485", "39087485" ], [ "Yanguo Shang, Shengnan Fu, Qingjing Hao, Hanjie Ying, Jinxin Wang, Tao Shen (2024). Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions. Bioorganic chemistry, 107092. https://doi.org/10.1016/j.bioorg.2023.107092 PMID: 38271825", "38271825" ], [ "Xinchao Zhao, Yawen Zheng, Yufeng Wang, Mingyan Zhang, Zhilin Dong, Yanan Liu, Meili Sun (2024). The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer. OncoTargets and therapy, 1041-1057. https://doi.org/10.2147/OTT.S484209 PMID: 39564454", "39564454" ], [ "Gerhard Hamilton, Sandra Stickler, Barbara Rath (2023). Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras. Current pharmaceutical design, 1741-1746. https://doi.org/10.2174/1381612829666230418114520 PMID: 37073657", "37073657" ], [ "Yi Chen, Qiu-Pei Liu, Hua Xie, Jian Ding (2023). From bench to bedside: current development and emerging trend of KRAS-targeted therapy. Acta pharmacologica Sinica. https://doi.org/10.1038/s41401-023-01194-4 PMID: 38049578", "38049578" ], [ "Na Li, Chen-Fu Liu, Wen Zhang, Guo-Wu Rao (2023). A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C). Current medicinal chemistry. https://doi.org/10.2174/0109298673258913231019113814 PMID: 37936461", "37936461" ], [ "Sajid Khan, Vivekananda Budamagunta, Daohong Zhou (2023). Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies. Advances in cancer research, 145-184. https://doi.org/10.1016/bs.acr.2023.02.004 PMID: 37268395", "37268395" ] ] ], [ [ "5DTM Crystal structure of Dot1L in complex with inhibitor CPD1 [4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide]", "4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide" ], 7.036307399999999 ], [ [ "DOT1L", "Etoposide" ], 0.73656195, [ [ "Yu Mao, Yu Sun, Zhixuan Wu, Jingzhi Zheng, Jianing Zhang, Jiaqi Zeng, Chunsik Lee, Jong Kyong Kim (2021). Targeting of histone methyltransferase DOT1L plays a dual role in chemosensitization of retinoblastoma cells and enhances the efficacy of chemotherapy. Cell death & disease, 1141. https://doi.org/10.1038/s41419-021-04431-y PMID: 34887387", "34887387" ], [ "Li-Hong Li, Jing Wang, Xiao-Yan Ke (2017). [Effects of DOT1L Inhibitor EPZ-5676 Combined with Chemotherapeutic Drugs on Prolifiration and Apoptosis of RS 4;11 Cells]. Zhongguo shi yan xue ye xue za zhi, 1334-1341. https://doi.org/10.7534/j.issn.1009-2137.2017.05.010 PMID: 29070104", "29070104" ], [ "Wei Liu, Lisheng Deng, Yongcheng Song, Michele Redell (2014). DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy. PloS one, e98270. https://doi.org/10.1371/journal.pone.0098270 PMID: 24858818", "24858818" ] ] ], [ [ "SOS1", "adagrasib" ], 23.571527, [ [ "Venu Thatikonda, Hengyu Lyu, Sabine Jurado, Kaja Kostyrko, Christopher A Bristow, Christoph Albrecht, Donat Alpar, Heribert Arnhof, Oliver Bergner, Karin Bosch, Ningping Feng, Sisi Gao, Daniel Gerlach, Michael Gmachl, Melanie Hinkel, Simone Lieb, Astrid Jeschko, Annette A Machado, Thomas Madensky, Ethan D Marszalek, Mikhila Mahendra, Gabriella Melo-Zainzinger, Jessica M Molkentine, Philipp A Jaeger, David H Peng, Robyn L Schenk, Alexey Sorokin, Sandra Strauss, Francesca Trapani, Scott Kopetz, Christopher P Vellano, Mark Petronczki, Norbert Kraut, Timothy P Heffernan, Joseph R Marszalek, Mark Pearson, Irene C Waizenegger, Marco H Hofmann (2024). Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance. Nature cancer, 1352-1370. https://doi.org/10.1038/s43018-024-00800-6 PMID: 39103541", "39103541" ], [ "Sandra Stickler, Barbara Rath, Gerhard Hamilton (2024). Targeting KRAS in pancreatic cancer. Oncology research, 799-805. https://doi.org/10.32604/or.2024.045356 PMID: 38686056", "38686056" ], [ "Fei Xiao, Kailiang Wang, Xinjuan Wang, Huijuan Li, Zhilong Hu, Xiaoming Ren, Wei Huang, Teng Feng, Lili Yao, Jing Lin, Chunlai Li, Zhuanzhuan Zhang, Liufeng Mei, Xiaotian Zhu, Wenge Zhong, Zhi Xie (2024). Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers. Molecular cancer therapeutics, 1703-1716. https://doi.org/10.1158/1535-7163.MCT-24-0049 PMID: 39087485", "39087485" ], [ "Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, Lars D Engstrom, Jade Laguer, Andrew Calinisan, Allan Hebbert, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, John M Ketcham, Anthony Ivetac, Christopher R Smith, J David Lawson, Lisa Rahbaek, Jeffrey Clarine, Natalie Nguyen, Barbara Saechao, Cody Parker, Adam J Elliott, Darin Vanderpool, Leo He, Laura D Hover, Julio Fernandez-Banet, Silvia Coma, Jonathan A Pachter, Jill Hallin, Matthew A Marx, David M Briere, James G Christensen, Peter Olson, Jacob Haling, Shilpi Khare (2024). The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading. Molecular cancer therapeutics, 1418-1430. https://doi.org/10.1158/1535-7163.MCT-23-0870 PMID: 38904222", "38904222" ], [ "Yanguo Shang, Shengnan Fu, Qingjing Hao, Hanjie Ying, Jinxin Wang, Tao Shen (2024). Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions. Bioorganic chemistry, 107092. https://doi.org/10.1016/j.bioorg.2023.107092 PMID: 38271825", "38271825" ], [ "Xinchao Zhao, Yawen Zheng, Yufeng Wang, Mingyan Zhang, Zhilin Dong, Yanan Liu, Meili Sun (2024). The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer. OncoTargets and therapy, 1041-1057. https://doi.org/10.2147/OTT.S484209 PMID: 39564454", "39564454" ], [ "Gerhard Hamilton, Sandra Stickler, Barbara Rath (2023). Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras. Current pharmaceutical design, 1741-1746. https://doi.org/10.2174/1381612829666230418114520 PMID: 37073657", "37073657" ], [ "Yi Chen, Qiu-Pei Liu, Hua Xie, Jian Ding (2023). From bench to bedside: current development and emerging trend of KRAS-targeted therapy. Acta pharmacologica Sinica. https://doi.org/10.1038/s41401-023-01194-4 PMID: 38049578", "38049578" ], [ "Na Li, Chen-Fu Liu, Wen Zhang, Guo-Wu Rao (2023). A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C). Current medicinal chemistry. https://doi.org/10.2174/0109298673258913231019113814 PMID: 37936461", "37936461" ], [ "Venu Thatikonda, Hengyu Lu, Sabine Jurado, Kaja Kostyrko, Christopher A Bristow, Karin Bosch, Ningping Feng, Sisi Gao, Daniel Gerlach, Michael Gmachl, Simone Lieb, Astrid Jeschko, Annette A Machado, Ethan D Marszalek, Mikhila Mahendra, Philipp A Jaeger, Alexey Sorokin, Sandra Strauss, Francesca Trapani, Scott Kopetz, Christopher P Vellano, Mark Petronczki, Norbert Kraut, Timothy P Heffernan, Joseph R Marszalek, Mark Pearson, Irene Waizenegger, Marco H Hofmann (2023). Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance. bioRxiv : the preprint server for biology. https://doi.org/10.1101/2023.01.23.525210 PMID: 36747713", "36747713" ] ] ] ] }